Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 5, 2013
HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: a prospective seriesPatrice Chevallier, Nelly Robillard, Marina Illiaquer, et al.Blood|August 21, 2010
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation studyPhilippe Moreau, Arnaud Jaccard, Lotfi Benboubker, et al.Transfusion|January 17, 2013
Characterization of various blood and graft sources: a prospective seriesPatrice Chevallier, Nelly Robillard, Marina Illiaquer, et al.The Laryngoscope|July 28, 2011
Relevance of both individual risk factors and occupational exposure in cancer survival studies: the example of intestinal type sinonasal adenocarcinomaDominique Tripodi, Christophe Ferron, Olivier Malard, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 12, 2017
Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adultsMarina Illiaquer, Berthe-Marie Imbert-Marcille, Thierry Guillaume, et al.Leukemia & Lymphoma|January 4, 2012
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myelomaCyrille Touzeau, Nicolas Blin, Aline Clavert, et al.Endoscopy|March 3, 2015
Screening of esophageal varices by esophageal capsule endoscopy: results of a French multicenter prospective studySylvie Sacher-Huvelin, Paul Calès, Christophe Bureau, et al.Blood|February 23, 2024
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myelomaCyrille Touzeau, Aurore Perrot, Cyrille Hulin, et al.Blood|March 19, 2015
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myelomaPhilippe Moreau, Brigitte Kolb, Michel Attal, et al.European Journal of Haematology|January 11, 2013
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)Amandine Le Bourgeois, Elsa Lestang, Thierry Guillaume, et al.Pageof 5